Continuous Glucose Monitoring Among Patients With Type 1 Diabetes in Rwanda (CAPT1D) Phase I: Prospective Observational Feasibility Study
Abstract BackgroundThe development of minimally invasive continuous glucose monitoring systems (CGMs) has transformed diabetes management. CGMs have shown clinical significance by improving time in the euglycemic range, decreasing rates of hypoglycemia, and improving hemoglobi...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
JMIR Publications
2025-01-01
|
| Series: | JMIR Formative Research |
| Online Access: | https://formative.jmir.org/2025/1/e64585 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Abstract
BackgroundThe development of minimally invasive continuous glucose monitoring systems (CGMs) has transformed diabetes management. CGMs have shown clinical significance by improving time in the euglycemic range, decreasing rates of hypoglycemia, and improving hemoglobin A1c1c
ObjectiveThis study aims to determine the impact and feasibility of real-time CGM use among people living with type 1 diabetes (T1D) in Rwanda through assessment of sensor use, time in range, rates of hypoglycemia and hyperglycemia, HbA1c
MethodsThe Continuous Glucose Monitoring Among Patients with Type 1 Diabetes in Rwanda (CAPT1D) study is a single-arm, prospective observational study conducted at the Rwandan Diabetes Association clinic in Kigali, Rwanda, aiming to assess the impact and feasibility of CGM use in Rwanda. A cohort of 50 participants diagnosed with T1D were enrolled. Participants were at least 21 years old, undergoing multiple daily insulin therapy, and not currently pregnant. Phase I of the study was conducted over 12 months, using the Dexcom G6 CGM. Phase II and Phase III extended CGM use for an additional 6 months respectively, using the next-generation Dexcom G7 CGM. Here, we report the quantitative results of the Phase I study.
ResultsParticipants used the sensor for >80% of the time throughout the study period. A significant increase in time in range was observed within 3 months and sustained over 12 months. HbA1c1cPP
ConclusionsSignificant and meaningful improvements in key glycemic indices indicate the potential feasibility and impact of a CGM among people living with T1D in Rwanda. Future studies could be designed to include pre- and postintervention analysis to determine the effectiveness in terms of complications and costs. |
|---|---|
| ISSN: | 2561-326X |